# Pizarra — PT-pseudo_138092c2a6be (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_138092c2a6be
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 9.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.16 ng/mL²
  - PSA velocity: 1.13 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86231947 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 58 mL. csPCa 0.86.

Vitals: weight 92 kg, height 191 cm, BMI 25.2, BP 134/69 mmHg, HR 75 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Clinical reassessment is required due to a confirmed prior biopsy and a continuing upward PSA trend.

History: First noted for an elevated PSA reading in 2022, this patient has since been managed within the outpatient setting. At fifty-two years of age, he works as a retired shopkeeper, lives with his wife in an assisted-living residence, and navigates daily life using a mobility frame. Moderate lower urinary tract symptoms yield an IPSS score of 16, yet he sustains a rigorous cycling regimen of roughly 30 kilometres three times weekly and restricts alcohol intake to five units per week. His medical background includes hypertension, Obesity (BMI >30), and osteoarthritis, managed with amlodipine, lisinopril, and paracetamol taken as needed. He remains a Current smoker (45 pack-yr). A recent routine surveillance colonoscopy returned normal results, and he reports no fresh pelvic pain or haematuria. A prior systematic biopsy identified low-volume disease, and his PSA continues to climb.

Physical examination: DRE: The prostate presents as symmetrically enlarged with a smooth, firm texture, lacking any palpable nodules or asymmetry. Vital signs remain stable, recording a blood pressure of 134/69 mmHg and a heart rate of 75 bpm. General observation shows a well-nourished individual walking with a standard mobility frame, exhibiting no acute distress or peripheral swelling.

Patient info: retired shopkeeper; Married; Lives in assisted-living facility.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.20   (95% CI 0.07-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 5.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=9.0, age=52.0, psad=0.16, dre_ord=0.0, vol=58.0, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=4, PSA=9.0, csPCa probability=0.86231947, DRE=Normal) and could not weigh the clinical context such as the prior positive biopsy status or the specific PSA velocity (1.13 ng/mL/yr).
The prior could not weigh the clinical significance of the prior positive biopsy result against the current findings, which is central to the decision.
The prior could not weigh the patient's specific PSA density (0.16 ng/mL²) or the specific PI-RADS 4 score in relation to the guideline's risk matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested 'NO BIOPSY' with a wide uncertainty interval (0.41 +/- 0.20), indicating the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input.
The suggestion could be wrong because the prior failed to account for the patient's prior positive biopsy status, which the EXPERT-PROTOCOL explicitly states is a critical factor that the visible panel alone cannot resolve.
The wide error bar suggests the classifier is operating in a 'discuss' tier, meaning the decision is highly ambiguous, and the clinical evidence retrieved is necessary to move beyond this statistical uncertainty.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive biopsy
laboratory panel - full panel
previous notes - context regarding the prior positive biopsy

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Maastricht UMC+
Prostatic volume registers at 58.0 mL. T2-weighted sequences highlight a roughly 18 mm focal hypointense area located at the base-to-mid junction of the left peripheral zone.
PI-RADS 4 lesion in the left peripheral zone.
csPCa predicted probability 0.86231947.

get_psa_trend
PSA trend shows a rising trajectory: Jun 2022: 1.7 ng/mL, Feb 2023: 2.6 ng/mL, Oct 2023: 3.9 ng/mL, Jun 2024: 5.9 ng/mL, Feb 2025: 9.0 ng/mL.

get_previous_notes
01 Sep 2023, Dr. C. Peters (GP): Clinical review highlighted a sustained PSA increase, currently tracking at 5.6 ng/mL after a mid-2022 baseline of 4.8 ng/mL. The case was forwarded to urology to initiate comprehensive evaluation and imaging planning.

get_lab_results
PSA: 9.0 ng/mL (20 Jan 2025, H).
%Free PSA: 25% (20 Jan 2025).
eGFR: >60 mL/min/1.73m2 (20 Jan 2025).

NOT RETRIEVED
The pathology report was not retrieved because the prompt stated it was not on file for this task.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity is 1.13 ng/mL/yr, indicating a significant current rise.
- mpMRI shows a PI-RADS 4 lesion (18 mm) in the left peripheral zone.
- PSA trend shows a clear upward trajectory, reaching 9.0 ng/mL in Feb 2025.

AGAINST sampling this patient now:
- DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly suggests that the combination of a rising PSA trend, a high PI-RADS score, and a significant PSA velocity warrants further investigation, leaning towards a recommendation for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence strongly suggests proceeding with biopsy due to the significant PSA velocity of 1.13 ng/mL/yr and the rising trend to 9.0 ng/mL. The retrieved PSA trend data and the mpMRI showing a PI-RADS 4 lesion provide the necessary clinical impetus to re-sample, as no documented prior grade or treatment pathway was established. The statistical prior suggested deferral, but the retrieved evidence of active disease progression overrides this initial suggestion.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
